ZBIO — Zenas BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953926 ·
Last close
$18.73
Market Cap
$1.18B
52W High
$26.98
52W Low
$16.41
ADV30
519,441
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -77,350,000 | -80,987,000 | 747,682,000 | 500,224,000 | 411,853,000 |
| Dec 2025 | 0 | — | -71,312,000 | -240,442,000 | 383,640,000 | 110,641,000 | 141,496,000 |
| Sep 2025 | 0 | — | -47,580,000 | -51,499,000 | 322,018,000 | 115,565,000 | 125,590,000 |
| Jun 2025 | 0 | — | -55,163,000 | -52,223,000 | 293,085,000 | 44,006,000 | 53,459,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-172,333,000
Investing CF
$-251,886,000
Financing CF
$215,280,000
CapEx
$-35,092,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-765,128,000
Inventory
—
Receivables
—
ST Investments
$232,551,000
EBIT TTM
$-370,489,000
Pretax Income TTM
$-377,816,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-251,366,000
Free Cash Flow
$-166,289,872
Enterprise Value
$747,264,192
Total Cash
$717,204,992
Total Debt
$266,828,992
Shares Out
63,133,377
Trailing EPS
$-9.10
Book Value
$4.44
ROE
-137.1%
ROA
-29.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -211,385,000 | -377,737,000 | 383,640,000 | 141,496,000 | — | -172,333,000 |
| Dec 2024 | 5,000,000 | -163,888,000 | -156,988,000 | 369,968,000 | 57,510,000 | — | -119,674,000 |
| Dec 2023 | 50,000,000 | -27,147,000 | -37,124,000 | 68,180,000 | 293,901,000 | — | -30,529,000 |
| Dec 2022 | 0 | -75,199,000 | -119,282,000 | 74,579,000 | 266,865,000 | — | -65,652,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.27
Max Pain — expiry 2027-01-15
max pain strike: $10.00 · spot: $18.73 · call oi: 1,064 · put oi: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $1.18B | $26.70 | — |
| OLMA | Olema Pharmaceuticals, Inc. | $1.18B | $13.55 | — |
| EVOTF | Evotec SE | $1.19B | $6.69 | — |
| SMNR | Semnur Pharmaceuticals, Inc. | $1.15B | $5.00 | — |
| WVE | Wave Life Sciences Ltd. | $1.23B | $6.38 | — |
News headlines (Yahoo Finance, 1h cache)
Insiders Buy the Dip in These 2 Crushed Stocks With Strong Buy Ratings
2026-05-21 17:58 · Yahoo
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
2026-05-19 11:05 · Yahoo
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 20:15 · Yahoo
Why Zenas BioPharma (ZBIO) Is Down 7.7% After Reporting a Sharply Wider Quarterly Net Loss
2026-05-13 17:28 · Yahoo
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
2026-05-13 10:50 · Yahoo
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 10:00 · Yahoo
IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi Leading
2026-05-07 11:34 · Yahoo
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks
2026-04-08 10:01 · Yahoo
Zenas BioPharma Funding Shifts Focus From Survival Risk To Execution Risk
2026-03-29 05:05 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-03-27 19:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.